News Releases

Non-Dilutive Funding to Accelerate Development of Artificial Intelligence Driven Handheld DeepView® LONDON, U.K. AND DALLAS, TX, U.S  -Spectral MD Holdings, Ltd. (AIM: SMD), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in

LONDON, U.K. AND DALLAS, TX, U.S.  -Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary artificial intelligence (AI) algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that it has granted options (“Options”)

Spectral MD is an Artificial Intelligence (AI) company focused on predictive medical diagnostics. The Company’s FDA Breakthrough Designated DeepView AI Wound Diagnostics platform (“DeepView”) uses proprietary algorithms to predict wound healing The proposed Transaction values Spectral MD at an

LONDON, U.K. AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care,announces that the Annual Report and Accounts for 2022 are now available on

Successful completion of clinical study enrollment paves way for next phase of BARDA funding Data used to finalize DeepView AI®-Burn algorithm LONDON, U.K. AND DALLAS, TX, U.S . -Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary artificial intelligence (AI)

LONDON, U.K. AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, is aware of public statements and media reports relating to Silicon Valley

Strong foundations laid ahead of planned regulatory submissions in 2023 LONDON, U.K. AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care,

Data from the study to support regulatory submissions on track for 2023 Participation from distinguished EU principal investigators provides significant endorsement for DeepView™    LONDON, U.K. AND DALLAS, TX, U.S  -Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with

LONDON, U.K. AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that, as at the date of this announcement, there are 136,201,515

DeepView® accuracy increases to 86% in diagnosis of DFU healing potential on day one LONDON, U.K. AND DALLAS, TX, U.S.  – Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in